Literature DB >> 6409035

[Bepridil and torsades de pointes].

J F Leclercq, S Kural, P E Valère.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6409035

Source DB:  PubMed          Journal:  Arch Mal Coeur Vaiss        ISSN: 0003-9683


× No keyword cloud information.
  7 in total

1.  Effects of bepridil on ventricular depolarization and repolarization of rabbit isolated hearts with particular reference to its possible proarrhythmic properties.

Authors:  T Osaka; I Kodama; J Toyama; K Yamada
Journal:  Br J Pharmacol       Date:  1988-04       Impact factor: 8.739

Review 2.  QT-interval prolonging drugs: mechanisms and clinical relevance of their arrhythmogenic hazards.

Authors:  M Zehender; S Hohnloser; H Just
Journal:  Cardiovasc Drugs Ther       Date:  1991-04       Impact factor: 3.727

3.  Effect of bepridil on metabolic control and insulin secretion in diabetics.

Authors:  S E Husted; C Pedersen; H K Nielsen; E Apoil; O H Nielsen; K Lindvig; L R Krusell; A Høegholm
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

4.  A comparison of bepridil with amiodarone in the treatment of established atrial fibrillation.

Authors:  M S Perelman; W J McKenna; E Rowland; D M Krikler
Journal:  Br Heart J       Date:  1987-10

5.  Electrophysiological action of bepridil on atrioventricular accessory pathways.

Authors:  P Touboul; G Atallah; G Kirkorian; P Lavaud; J R Kieny; M P Mathieu; A Dellinger
Journal:  Br Heart J       Date:  1987-10

Review 6.  Bepridil. A review of its pharmacological properties and therapeutic use in stable angina pectoris.

Authors:  L M Hollingshead; D Faulds; A Fitton
Journal:  Drugs       Date:  1992-11       Impact factor: 9.546

Review 7.  Bepridil: a pharmacological reappraisal of its potential beneficial effects in angina and tissue protection following ischemia.

Authors:  R Massingham; P A Van Zwieten
Journal:  Cardiovasc Drugs Ther       Date:  1989-10       Impact factor: 3.727

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.